Esperion Therapeutics (ESPR) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
9 Jul, 2026Opening remarks and agenda
Chairperson called the meeting to order at 8:00 A.M. and outlined the rules of conduct and agenda.
Notice of the meeting and proxy statement were distributed to stockholders of record as of May 28, 2026.
Quorum was confirmed, with a majority of voting power present virtually or by proxy.
Specific resolutions to be voted on
Approval of the Agreement and Plan of Merger with Essence Parent and Essence MergerCo, making the company a wholly owned subsidiary.
Advisory vote on compensation for named executive officers in connection with the merger.
Approval to adjourn the meeting if additional proxy solicitation was needed.
Overview of voting outcomes
Merger Agreement Proposal was approved by a majority of outstanding shares.
Advisory Compensation Proposal was approved by a majority of outstanding shares.
Adjournment Proposal was not addressed as the merger was approved.
Final vote counts to be reported in a Form 8-K filing within four business days.
Latest events from Esperion Therapeutics
- Revenue up 186% in FY24; global expansion and pipeline drive 2025 growth targets.ESPR
Q4 20249 Jul 2026 - Next-gen ACLY inhibitor targets PSC with strong preclinical data and phase I trials planned for 2026.ESPR
Status Update8 Jul 2026 - Adjusted revenue up 63% year-over-year; U.S. net product revenue rose 41%; net loss $40.5M.ESPR
Q1 20258 Jul 2026 - Q2 revenue up 186% YoY, liquidity strengthened, and expanded labels fuel future growth.ESPR
Q2 20248 Jul 2026 - Stockholders will vote July 8, 2026, on a merger with Essence Parent Inc. after regulatory clearance.ESPR
Proxy filing16 Jun 2026 - Shareholders to vote on merger with $3.16 cash per share plus CVR; Board recommends approval.ESPR
Proxy filing8 Jun 2026 - Shareholders to vote on a merger with $3.16/share cash and CVR; board recommends approval.ESPR
Proxy filing29 May 2026 - All proposals passed, with no shareholder questions and strong support for board recommendations.ESPR
AGM 202628 May 2026 - Corstasis acquisition and sustained growth drive expansion in heart failure and global markets.ESPR
The Citizens Life Sciences Conference 202617 May 2026